3-(Boc-氨基)-3-(4-氯苯基)丙酸 | 284493-65-8

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 中文名称: 3-(Boc-氨基)-3-(4-氯苯基)丙酸
• 中文别名: 3-(BOC-氨基)-3-(4-氯苯基)丙酸；N-叔丁氧羰基-3-氨基-3-(4'-氯苯基)丙酸；3-N-boc-氨基-3-(4-氯苯基)丙酸
• 英文名称: 3-[(tert-butoxycarbonyl)amino]-3-(4-chlorophenyl)propanoic acid
• 英文别名: 3-tert-butoxycarbonylamino-3-(4-chlorophenyl)propionic acid；tert-butyl-3-amino-3-(4-chlorophenyl)propanoic acid；3-((tert-Butoxycarbonyl)amino)-3-(4-chlorophenyl)propanoic acid；3-(4-chlorophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 284493-65-8
• 化学式: C₁₄H₁₈ClNO₄
• 分子量: 299.754
• InChiKey: ZPXVKCUGZBGIBW-UHFFFAOYSA-N

物化性质

• 熔点：
  95-96°C
• 沸点：
  453.9±40.0 °C(Predicted)
• 密度：
  1.243
• 稳定性/保质期：
  避免接触氧化物、高温及火焰。

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	3-N-BOC-Amino-3-(4-Chlorophenyl)Propionic Acid 95% Material Safety Data Sheet
Synonym:	3-N-(tert-Butoxycarbonyl)-Amino-3-(4-Chlorophenyl)Propionic Acid
CAS:	284493-65-8

Section 1 - Chemical Product MSDS Name:3-N-BOC-Amino-3-(4-Chlorophenyl)Propionic Acid 95% Material Safety Data Sheet
Synonym:3-N-(tert-Butoxycarbonyl)-Amino-3-(4-Chlorophenyl)Propionic Acid

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
284493-65-8	3-N-BOC-Amino-3-(4-Chlorophenyl)Propio	95%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 284493-65-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H18ClNO4
Molecular Weight: 299.75

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 284493-65-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-N-BOC-Amino-3-(4-Chlorophenyl)Propionic Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 284493-65-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 284493-65-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 284493-65-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(Boc-氨基)-3-(4-氯苯基)丙酸 在 氯化铵 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以82%的产率得到tert-butyl 3-amino-1-(4-chlorophenyl)-3-oxopropylcarbamate
  参考文献：
  名称：

  [EN] PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS
  [FR] DÉRIVÉS PYRROLO[2,3-D]PYRIMIDINE COMME INHIBITEURS DE LA PROTÉINE KINASE B

  摘要：

  该发明涉及一类新型化合物，其化学式为（I）或其盐：其中Y、Z1、Z2、R1、R4、R5和n如规范中所述，这些化合物可能在通过蛋白激酶B（PKB）介导的疾病或医疗状况的治疗或预防中有用，例如癌症。该发明还涉及包含所述化合物的药物组合物，使用所述化合物治疗通过PKB介导的疾病的方法，以及制备化合物（I）的方法。

  公开号：

  WO2009047563A1
• 作为产物：
  描述：

  4-氯苯甲醛 在 ammonium acetate 、 三乙胺 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 5.0h， 生成 3-(Boc-氨基)-3-(4-氯苯基)丙酸
  参考文献：
  名称：

  Annulation of 2H-Pyran onto 1-Oxa- or 1-Azacyclohexane-2,4-diones and Their Analogues via Sequential Condensation with α-Substituted Enals and 6π-Electrocyclization

  摘要：

  通过Knoevenagel缩合反应与烯醛反应，随后进行6π-电环化反应，以1-氧杂-或1-氮杂环己烷-2,4-二酮为核心构建了2H-吡喃衍生物，这些反应易于用乙二胺二乙酸盐催化。这种形式上的[3 + 3]策略构成了C–O和C–C键的形成，并通过在1-氧杂环己烷-2,4-二酮中使用相同的芳基进行6,6-二取代来避免立体异构体的形成。这种简便的方法学极大地促进了多取代双环2H-吡喃的合成，具有多样化的底物选择和产品稳定性的提高。

  DOI：

  10.1246/bcsj.20130069

文献信息

• [EN] COMPOUNDS HAVING A FUNGICIDAL ACTIVITY, THEIR AGRONOMIC COMPOSITIONS AND USE THEREOF FOR THE CONTROL OF PHYTOPATHOGENIC FUNGI<br/>[FR] COMPOSÉS AYANT UNE ACTIVITÉ FONGICIDE, LEURS COMPOSITIONS AGRONOMIQUES ET LEUR UTILISATION POUR LUTTER CONTRE DES CHAMPIGNONS PHYTOPATHOGÈNES
  申请人：ISAGRO SPA

  公开号：WO2020225700A1

  公开（公告）日：2020-11-12

  Compounds having general formula (I) with a high fungicidal activity and their use for the control of phytopathogenic fungi of important agricultural crops, are described.

  具有通式（I）的化合物具有很高的杀真菌活性，并且它们用于控制重要农作物的植物病原真菌。
• [EN] SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME<br/>[FR] TRIAZOLES AMINO-SUBSTITUÉS ET PROCÉDÉS D'UTILISATION
  申请人：INST DRUG DELIVERY

  公开号：WO2015095701A1

  公开（公告）日：2015-06-25

  Disclosed are novel substituted amino triazoles of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of Formula (I) are inhibitors of Acidic mammalian chitinase (AMCase) and are useful, in a non-limiting example, for treating asthma. Also provided are pharmaceutical compositions containing at least one compound of the present invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluent, and methods of using such compounds and/or compositions to treat asthma and/or to monitor asthma treatment.

  公开了化合物的新型替代氨基三唑的结构，其化学式为（I），以及其药学上可接受的盐。化合物的化学式（I）是酸性哺乳动物几丁质酶（AMCase）的抑制剂，并且在非限制性示例中用于治疗哮喘。还提供了含有本发明至少一种化合物或其药学上可接受的盐、水合物或溶剂化合物的药物组合物，以及至少一种药学上可接受的载体、溶剂、辅料或稀释剂，并使用这些化合物和/或组合物来治疗哮喘和/或监测哮喘治疗的方法。
• [EN] BICYCLIC QUINAZOLINONE DERIVATIVES<br/>[FR] DÉRIVÉS DE QUINAZOLINONE BICYCLIQUE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2016162390A1

  公开（公告）日：2016-10-13

  The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R12, R13, R14, A1, A2, A3, n and m are as described herein.

  该发明提供了具有一般式（I）的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R12、R13、R14、A1、A2、A3、n和m如本文所述。
• Novel compounds for treatment of cancer and disorders associated with angiogenesis function
  申请人：Neamati Nouri

  公开号：US20060142294A1

  公开（公告）日：2006-06-29

  Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, breast cancer, renal cancer, and prostate cancer) and disorders associated with angiogenesis function (e.g., age-related macular degeneration, macular dystrophy, and diabetes), a method of monitoring the treatment, a method of profiling gene expression, and a method of modulating gene expression.

  用于治疗癌症和与血管生成功能相关疾病的新化合物。还公开了一种制备这些化合物的方法，包括含有这些化合物的药物组合物和包装产品，一种使用这些分子治疗癌症（例如白血病、非小细胞肺癌、结肠癌、中枢神经系统癌症、黑色素瘤、卵巢癌、乳腺癌、肾癌和前列腺癌）和与血管生成功能相关疾病（例如年龄相关性黄斑变性、黄斑营养不良和糖尿病）的方法，一种监测治疗效果的方法，一种基因表达分析的方法，以及一种调控基因表达的方法。
• Probes, systems, and methods for drug discovery
  申请人：——

  公开号：US20030125315A1

  公开（公告）日：2003-07-03

  Aspects of the present invention include probes, methods, systems that have stand alone utility and may comprise features of a drug discovery system or method. The present invention also includes pharmaceutical compositions. In more detail, the present invention provides molecular probes and methods for producing molecular probes. The present invention provides also provides systems and methods for new drug discovery. An embodiment of the present invention utilizes sets of probes of the present invention and a new approach to computational chemistry in a drug discovery method having increased focus in comparison to heretofore utilized combinatorial chemistry. The present invention also provides computer software and hardware tools useful in drug discovery systems. In an embodiment of a drug discovery method of the present invention in silico methods and in biologico screening methods are both utilized to maximize the probability of success while minimizing the time and number of wet laboratory steps necessary to achieve the success.

  本发明的方面包括探针、方法、系统，具有独立实用性并可能包括药物发现系统或方法的特征。本发明还包括制药组合物。更详细地说，本发明提供了分子探针和制备分子探针的方法。本发明还提供了新药物发现的系统和方法。本发明的实施例利用本发明的探针集和一种新的计算化学方法在药物发现方法中具有更高的聚焦度，相比之前使用的组合化学方法。本发明还提供了在药物发现系统中有用的计算机软件和硬件工具。在本发明的药物发现方法的实施例中，同时利用了基于计算机的方法和生物筛选方法，以最大化成功的可能性，同时最小化必要的湿实验步骤的时间和数量。